Table 5.

Influence of continued accelerated bone resorption (urine NTX) on risk of death

Relative risk (95% CI)P
NTX ≥100 vs NTX <50
    Prostate cancer5.72 (4.04-8.11)<0.001
    Breast cancer4.84 (3.19-7.32)<0.001
    NSCLC3.87 (2.48-6.04)<0.001
    Myeloma2.06 (0.25-16.43)<0.496
    Others4.54 (2.71-7.58)<0.001
BAP ≥146 vs BAP <146 IU
    Prostate cancer4.22 (2.80-6.35)<0.001
    Breast cancer3.73 (2.62-5.29)<0.001
    NSCLC1.78 (1.34-2.36)<0.001
    Myeloma3.02 (1.54-5.95)0.001
    Others2.23 (1.64-3.03)<0.001
  • NOTE: Data adapted from ref. 32 and presented as a table.